UA121701U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

Method for diagnosing the development of atherosclerosis, including clinical examination, examination of low and high density lipoprotein cholesterol levels, arteriography, determination of MTHFR C677T gene polymorphism in serum, thrombomodulin content, folic acid, SRP, TG7, TF7 , thrombomodulin levels> 5 ng / ml, folic acid <6 ng / ml, SRP> 6 mg / l, TGF- (1 <14 ng / ml diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (A.N. Okorokov.

Diagnosis of diseases of internal organs. -- T. 6-S. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that along with the study of low and high density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEK C677T), the content of thrombomodulin, folic acid, C-reactive protein (CRP), transforming growth factor beta 1 (TFR-

B1). With homozygous carrier 677-TT, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SRP "6 mg/l, TFR-B1 "14 ng/ml, the development of atherosclerosis is diagnosed.

Application of the method. Upon admission, the patient is examined, low-density lipoprotein and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. The polymorphism of the MTNEK C677T gene is determined in the patient's blood serum. The content of thrombomodulin, folic acid, SRP, TGF-B1 is determined by the immunoenzymatic method. With homozygous carrier 677-TT, levels of thrombomodulin "5 ng/ml, folic acid "b ng/ml, SRP "b mg/l, TGF-B1 "14 ng/ml diagnose the development of atherosclerosis.

A specific example of using the method.

Patient B., 48 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis.

Examined Low and high density lipoprotein cholesterol levels were studied. An arteriography of vessels was performed. There are no signs of atherosclerosis. The MTNEK C677T gene polymorphism was determined in blood serum. The content of thrombomodulin, folic acid, SRP, TGF-B1 was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of thrombomodulin - 8 ng/ml, folic acid -3.8 ng/ml, SRP - 18 mg/l, TFR-(31-6.8 ng/ml). The development of atherosclerosis was diagnosed. Arteriographic signs of atherosclerosis were established only after 14 months.

Thus, the proposed method allows diagnosing atherosclerosis in the early stages of the process.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, low- and high-density lipoprotein cholesterol levels, arteriography, determination of the MTNEV C677T gene polymorphism, thrombomodulin, folic acid, SRP, TFR-RI1 content in blood serum, which differs in that with homozygous carrier 677-TT, levels of thrombomodulin 25 ng/ml, folic acid "b ng/ml, SRP "b mg/l, TFR-D1 "14 ng/ml diagnose the development of atherosclerosis.